Fritz Blatter

USPTO Granted Patents = 57 (Patent Applications = 20)

CIPO Patents = 9 (Patent Applications = 12)

EPO Patents = 25 (Patent Applications = 44)

Average Co-Inventor Count = 4.5

ph-index = 10

Forward Citations = 250(Granted Patents)

Forward Citations (Not Self Cited) = 232(Oct 12, 2025)

Location History:

Berkeley, CA (US) (1998)
Reinach BL, DE (2011)
Reinach, SE (2012)
Basel, CH (1999 - 2013)
Reinach, CH (2008 - 2024)

Company Filing History:

Acadia Pharmaceuticals Inc.

patents

5. 4 out of 135

Biomarin Pharmaceutical Inc.

University of California

Anadys Pharmaceuticals, Inc.

patents

10. 3 out of 104

Intervet International B.v.

patents

11. 2 out of 1,235

Nissan Chemical Industries Limited

Ciba Specialty Chemicals Corporation

patents

15. 1 out of 27

Vifor (international) Ag

Teva Pharmaceutical Industries Limited

patents

Years Active: 1998-2025

Loading Chart...

57 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12221446 - Crystalline salt of 5-methyl-(6S)-tetrahydrofolic acid and L-isoleucine ethyl ester (2025-02-11),

2. 12221445 - Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and amino ethyl esters (2025-02-11),

3. 12048700 - Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid (2024-07-30),

4. 11992491 - Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester (2024-05-28),

5. 11925644 - Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and l-leucine ethyl ester (2024-03-12),

6. 11820777 - Crystal forms of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide (2023-11-21),

7. 11633400 - Crystalline salt comprising 5-methyl-(6S)-tetrahydrofolic acid and 4-(2-hydroxyethyl)-morpholine (2023-04-25),

8. 11377448 - Crystalline sodium salt of 5-methyl-(6S)-tetrahydrofolic acid (2022-07-05),

9. 11185545 - Crystalline monosodium salt of 5-methyl-(6S)-tetrahydrofolic acid (2021-11-30),

10. 11129820 - Ferroportin-inhibitor salts (2021-09-28),

11. 11066408 - Crystalline binary sodium salts of 5-methyl-(6S)-tetrahydrofolic acid with organic bases (2021-07-20),

12. 11059829 - Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate (2021-07-13),

13. 10640509 - Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide for treating diffuse large B-cell lymphoma (2020-05-05),

14. 10167291 - Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide (2019-01-01),

15. 10045998 - Solid form of abiraterone acetate (2018-08-14),

Title: The Innovative Journey of Inventor Fritz Blatter

Introduction:

In the realm of inventions and patents, one standout figure is Fritz Blatter, hailing from Reinach, Switzerland. With an impressive portfolio of 47 patents, Blatter has left an indelible mark in the field of pharmaceutical innovations.

Latest Patents:

Among his latest patents, two notable creations stand out: Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-valine ethyl ester, and Crystalline salts of 5-methyl-(6S)-tetrahydrofolic acid and L-leucine ethyl ester. These inventions focus on specific crystalline salt compositions, alongside their respective processes of production.

Career Highlights:

Throughout his career, Blatter has made significant contributions while working with prestigious companies such as BASF SE Corporation and Merck Patent GmbH. His expertise and dedication have led to groundbreaking advancements in the pharmaceutical industry, showcasing his prowess as a prolific inventor.

Collaborations:

In his pursuit of innovation, Blatter has collaborated closely with esteemed individuals in the field. Notable coworkers include Martin Szelagiewicz and Rudolf Moser, both of whom have contributed to the success of various projects alongside Blatter.

Conclusion:

Inventor Fritz Blatter's journey exemplifies a relentless pursuit of innovation and excellence in the world of pharmaceutical inventions. With his array of patents and impactful collaborations, Blatter continues to shape the landscape of pharmaceutical advancements, leaving a lasting legacy in the industry.

This text is generated by artificial intelligence and may not be accurate.